Your browser is no longer supported. Please, upgrade your browser.
Settings
PSTI Pluristem Therapeutics Inc. daily Stock Chart
PSTI [NASD]
Pluristem Therapeutics Inc.
Index- P/E- EPS (ttm)-8.02 Insider Own6.04% Shs Outstand17.83M Perf Week-14.38%
Market Cap67.93M Forward P/E- EPS next Y-0.88 Insider Trans0.00% Shs Float16.78M Perf Month0.79%
Income-31.30M PEG- EPS next Q-0.25 Inst Own7.70% Short Float0.53% Perf Quarter12.72%
Sales0.02M P/S2953.58 EPS this Y55.20% Inst Trans13.01% Short Ratio0.56 Perf Half Y8.86%
Book/sh1.00 P/B3.81 EPS next Y33.10% ROA-122.40% Target Price15.13 Perf Year-62.28%
Cash/sh0.90 P/C4.22 EPS next 5Y- ROE-196.30% 52W Range3.11 - 10.20 Perf YTD-3.30%
Dividend- P/FCF- EPS past 5Y-46.50% ROI- 52W High-62.65% Beta1.67
Dividend %- Quick Ratio2.80 Sales past 5Y- Gross Margin- 52W Low22.51% ATR0.24
Employees160 Current Ratio2.80 Sales Q/Q-54.00% Oper. Margin- RSI (14)42.84 Volatility5.01% 5.87%
OptionableYes Debt/Eq0.00 EPS Q/Q46.70% Profit Margin- Rel Volume1.03 Prev Close4.07
ShortableYes LT Debt/Eq0.00 EarningsFeb 26 Payout- Avg Volume158.25K Price3.81
Recom1.70 SMA20-5.23% SMA50-3.63% SMA200-13.74% Volume160,827 Change-6.39%
Dec-16-19Initiated Dawson James Buy $12
Jul-22-19Initiated Ladenburg Thalmann Buy
Feb-13-17Downgrade Maxim Group Buy → Hold
Jul-19-16Resumed H.C. Wainwright Buy $3.50
Dec-22-15Reiterated Maxim Group Buy $8 → $3
Feb-03-15Reiterated Needham Buy $5 → $4
Sep-22-14Resumed Oppenheimer Outperform
Sep-08-14Initiated H.C. Wainwright Buy $4
Jan-21-14Reiterated MLV & Co Buy $4.50 → $6
Sep-16-13Upgrade Maxim Group Hold → Buy $8
Jun-04-13Downgrade Maxim Group Buy → Hold
May-31-13Initiated MLV & Co Buy $4.50
Jul-25-12Initiated Maxim Group Buy $8
Jul-24-12Downgrade WBB Securities Speculative Buy → Hold $4 → $3.75
May-22-12Initiated Needham Buy $5
Dec-09-11Initiated Global Hunter Securities Speculative Buy $5
Jun-17-11Initiated Dawson James Buy $5
May-17-11Initiated Oppenheimer Outperform $5
Mar-01-11Initiated WBB Securities Speculative Buy $4
Jan-10-11Initiated National Securities Buy
Feb-10-20 07:00AM  Pluristem Therapeutics CEO Issues Shareholder Update GlobeNewswire
Feb-03-20 07:00AM  In Its Path Towards Marketing, Pluristem Provides Highly Favorable Market Access Data Regarding the Critical Limb Ischemia Market in U.S. GlobeNewswire +5.08%
Jan-09-20 11:53AM  Does The Pluristem Therapeutics Inc. (NASDAQ:PSTI) Share Price Fall With The Market? Simply Wall St.
Dec-17-19 07:00AM  Pluristem Completes 75% Enrollment in its Pivotal Phase III CLI Clinical Study GlobeNewswire +13.17%
Dec-11-19 06:40AM  Pluristem Therapeutics Shares March Higher, Can It Continue? Zacks
Dec-03-19 07:00AM  Pluristem Reaches Milestone in its Phase III Muscle Injury Study, Completes 50% Enrollment GlobeNewswire +5.26%
Nov-30-19 11:40AM  Hedge Funds Have Never Been More Bullish On Pluristem Therapeutics Inc. (PSTI) Insider Monkey
Nov-19-19 11:06AM  Pluristem Therapeutics (NASDAQ:PSTI) Will Have To Spend Its Cash Wisely Simply Wall St.
Nov-12-19 07:00AM  Pluristem Therapeutics CEO Issues Shareholder Update GlobeNewswire
Nov-04-19 07:00AM  RESTORE Consortium to Host the 1st Advanced Therapies Science Meeting, Aiming to Translate Promising Research into a Game Changer in Healthcare GlobeNewswire -5.46%
Oct-28-19 11:16AM  Pluristem Therapeutics Sees Hammer Chart Pattern: Time to Buy? Zacks
Oct-08-19 02:00PM  Pluristem Therapeutics Inc. (NASDAQ:PSTI) Insiders Increased Their Holdings Simply Wall St.
Sep-16-19 12:20PM  Pluristem Therapeutics Recaps Key Opinion Leader Call Reviewing Hematological Programs GlobeNewswire
Sep-09-19 07:00AM  Pluristem Therapeutics to Host Key Opinion Leader Call on Its Acute Radiation Syndrome and Hematological Programs GlobeNewswire
Sep-05-19 09:24AM  Did Changing Sentiment Drive Pluristem Therapeutics's (NASDAQ:PSTI) Share Price Down A Painful 86%? Simply Wall St. +10.42%
Aug-21-19 07:00AM  Pluristem Therapeutics to Host Key Opinion Leader Call on its Acute Radiation Syndrome and Hematological Deficiencies Programs GlobeNewswire
Jul-31-19 08:00AM  Pluristem and U.S. Department of Defense Present Positive Data from Studies Testing PLX-R18 as a Prophylactic Treatment for Acute Radiation Syndrome GlobeNewswire
08:00AM  OFFICIAL CORRECTION-Pluristem gets positive results from radiation treatment trials Reuters
Jul-25-19 07:21AM  The Daily Biotech Pulse: Setback For Bristol-Myers Squibb, Gemphire Explodes, Lilly's Nasal Low Blood Sugar Drug Benzinga +6.34%
Jul-24-19 10:45AM  Pluristem Therapeutics CEO Issues Shareholders Update GlobeNewswire -25.08%
07:08AM  The Daily Biotech Pulse: Jounce Jumps On Licensing Deal, Regulus Hit With Partial Clinical Hold, Genomic Health Added to S&P SmallCap Index Benzinga
02:45AM  Pluristem Announces One-for-Ten Reverse Split of its Common Shares GlobeNewswire
Jul-22-19 09:33AM  What Kind Of Investor Owns Most Of Pluristem Therapeutics Inc. (NASDAQ:PSTI)? Simply Wall St.
Jul-17-19 07:00AM  Pluristem and U.S. Department of Defense to Announce Data from Studies Testing PLX-R18 as a Prophylactic Treatment for Acute Radiation Syndrome at RITN GlobeNewswire +6.11%
Jul-02-19 07:00AM  Pluristem Therapeutics CEO Issues Shareholder Letter GlobeNewswire
Jun-24-19 07:00AM  Pluristem Completes Transition Period of Co-CEO Structure Yaky Yanay appointed as Chief Executive Officer and Zami Aberman appointed as Executive Chairman of the Board GlobeNewswire
Jun-17-19 07:00AM  Pluristem Strengthens Its Manufacturing Competitive Advantage, Presents its First Proprietary Serum-Free Cell Therapy Product GlobeNewswire
Jun-14-19 01:58PM  Pluristem Therapeutics Inc. (NASDAQ:PSTI): Are Analysts Optimistic? Simply Wall St.
May-15-19 07:00AM  Lead Physicians in Pluristems Pivotal Study in Critical Limb Ischemia Publish Peer-Reviewed Paper GlobeNewswire
May-06-19 07:00AM  Pluristem Files Patent Application for the Use of its Advanced Manufacturing Technology in the Cannabis Industry GlobeNewswire
Apr-29-19 07:00AM  Pluristem Completes Interim Enrollment in Pivotal CLI Study, Targeting Potential Conditional Marketing Approval in Europe GlobeNewswire +5.93%
Apr-28-19 09:02AM  Does The Pluristem Therapeutics Inc. (NASDAQ:PSTI) Share Price Tend To Follow The Market? Simply Wall St.
Apr-23-19 08:00AM  Pluristem Therapeutics Issues Shareholder Update GlobeNewswire
Apr-04-19 09:17AM  Pluristem Therapeutics Inc. Announces Pricing of Its Public Offering and Registered Direct Offering for Aggregate Proceeds of Approximately $20 Million GlobeNewswire -32.75%
07:58AM  The Daily Biotech Pulse: Recro Restructures, Biotechs Raise Proceeds In Droves, Silk Road, NGM Biopharma To Debut Benzinga
Apr-03-19 04:51PM  Pluristem Therapeutics Inc. Announces Proposed Public Offering of Common Stock and Warrants and Concurrent Registered Direct Offering of Common Stock GlobeNewswire -8.75%
Mar-12-19 08:00AM  Pluristem Therapeutics Announces Completion of 2nd Cohort and DSMB Approval to Enroll Final Cohort in Phase I Hematological Study of PLX-R18 GlobeNewswire
Mar-07-19 11:01AM  Is Pluristem Therapeutics Inc.s (NASDAQ:PSTI) Balance Sheet A Threat To Its Future? Simply Wall St.
Feb-20-19 07:30AM  Pluristem Enters into Collaboration with NASA to Study PLX Therapeutic Benefits in Space Missions GlobeNewswire
Feb-14-19 06:06AM  Pluristem Therapeutics Sees Hammer Chart Pattern: Time to Buy? Zacks
Feb-11-19 10:19AM  RESTORE Consortium, of which Pluristem is a member, Nominated to Be One of Two Finalists Competing for a Potential Award for Development of Advanced Therapeutics GlobeNewswire
Feb-07-19 03:31PM  Pluristem: Fiscal 2Q Earnings Snapshot Associated Press
Jan-28-19 11:41AM  Read This Before Buying Pluristem Therapeutics Inc. (NASDAQ:PSTI) Shares Simply Wall St.
Jan-22-19 07:00AM  Pluristem to Collaborate with Israeli Ministry of Defense in the Treatment of Burn Injuries GlobeNewswire
Jan-09-19 08:00AM  Pluristem Therapeutics Reports Successful Case Study in Treatment of Buergers Disease Patient GlobeNewswire +5.66%
Jan-03-19 08:30AM  Pluristem Concludes Positive Meeting with FDA on Development Plan for Acute Radiation Syndrome GlobeNewswire +7.32%
Dec-17-18 08:40AM  Pluristem Therapeutics Recaps Key Opinion Leader Meeting on Peripheral Artery Disease (PAD) GlobeNewswire
Dec-13-18 11:59AM  Reminder- Pluristem Therapeutics to Host Key Opinion Leader Meeting on Peripheral Artery Disease Tomorrow GlobeNewswire
Dec-04-18 07:00AM  Pluristem Therapeutics Enters into Cell Thawing Device License Agreement with Chart Industries, Inc. GlobeNewswire
Dec-03-18 07:00AM  Pluristem Presents Data from First Cohort in Ongoing Phase I Hematological Study at the American Society of Hematology (ASH) Annual Meeting GlobeNewswire
Nov-30-18 05:32AM  Pluristem Therapeutics Sees Hammer Chart Pattern: Time to Buy? Zacks
Nov-29-18 07:30AM  The Real Impact of PAD - Pluristem Therapeutics to Host Key Opinion Leader Meeting on Peripheral Artery Disease GlobeNewswire
Nov-28-18 08:00AM  Pluristem to Present First Cohort Data from PLX-R18 Hematological Study at American Society of Hematologys (ASH) Annual Meeting GlobeNewswire
Nov-20-18 11:20AM  What Kind Of Investor Owns Most Of Pluristem Therapeutics Inc (NASDAQ:PSTI)? Simply Wall St.
Nov-19-18 08:15AM  Report: Exploring Fundamental Drivers Behind Pluristem Therapeutics, RXi Pharmaceuticals, Saga Communications, Global Self Storage, Sequential Brands Group, and Finjan New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Nov-12-18 07:30AM  New Findings from Pluristems Phase II IC study: PLX-PAD Cells Significantly Improves Blood Glucose Control (HbA1c) and Reduce Chronic Inflammation GlobeNewswire
Nov-08-18 10:42AM  Pluristem: Fiscal 1Q Earnings Snapshot Associated Press
07:00AM  Pluristem Therapeutics Reports Fiscal 2019 First Quarter Results and Provides Corporate Update GlobeNewswire
Oct-18-18 06:30AM  Pluristem Therapeutics Selected to Present Data from Phase II IC Study at the American Heart Association Scientific Sessions GlobeNewswire
Oct-16-18 07:00AM  U.S. FDA Approves Cost Recovery for PLX-PAD under Expanded Access Program in the Treatment of Critical Limb Ischemia GlobeNewswire
Oct-10-18 07:00AM  Pluristem Therapeutics Announces Publication in JCSM of Two-Year Follow-Up Data from Phase I/II Study in Muscle Regeneration and European Clearance for Ongoing Phase III Study GlobeNewswire
Sep-27-18 07:00AM  Pluristem Reports Fiscal 2018 Fourth Quarter Results and Provides Corporate Update GlobeNewswire
Sep-20-18 12:10PM  What does Pluristem Therapeutics Incs (NASDAQ:PSTI) Balance Sheet Tell Us About Its Future? Simply Wall St.
Aug-08-18 07:00AM  Pluristem Initiates Two Pivotal Phase III Studies in Israel GlobeNewswire
Jul-31-18 03:16PM  Pluristem Therapeutics, Rexahn Pharma Are Biotech Winners, B Riley FBR Says In Bullish Initiation Benzinga
Jul-26-18 07:00AM  Pluristem Granted Key Patent in Japan for Treatment of GI Following Acute Radiation Exposure GlobeNewswire
Jul-19-18 07:05AM  Free Technical Reports on Portola Pharma and Three Additional Biotech Equities ACCESSWIRE
Jul-09-18 07:00AM  Pluristem Signs Collaboration Agreement With Thermo Fisher Scientific GlobeNewswire
Jun-25-18 07:26AM  Pluristem shares jump 2% on news of positive trial of treatment for radiation damage MarketWatch
07:00AM  Pluristem and Fukushima University Report Positive Data: PLX-R18 Increases Survival Rates and Mitigates Severe Intestinal Damage after Acute Radiation Exposure GlobeNewswire
Jun-19-18 07:00AM  U.S. Department of Defense to Study Pluristems PLX-R18 for the Treatment of Mustard Gas Injuries GlobeNewswire
Jun-14-18 07:00AM  Pluristem to Open Weekly Market Trading at TASE Following Positive Study Results GlobeNewswire -5.26%
Jun-13-18 08:12PM  Should You Be Content With Pluristem Therapeutics Incs (NASDAQ:PSTI) Earnings Growth? Simply Wall St.
Jun-12-18 09:23AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga -6.43%
06:38AM  Israel's Pluristem sees positive results from leg pain study Reuters
06:00AM  Pluristem Reports Positive Top-Line Results from Its Multinational Phase II Intermittent Claudication Study GlobeNewswire
Jun-05-18 09:48AM  Options Traders Expect Huge Moves in Pluristem Therapeutics (PSTI) Stock Zacks
Jun-04-18 06:00AM  Pluristem to Announce Top-Line Results of Its Multinational Phase II Intermittent Claudication Study on June 12, 2018 GlobeNewswire
May-16-18 04:43PM  Pluristem Therapeutics Inc (NASDAQ:PSTI): Are Analysts Optimistic? Simply Wall St.
May-10-18 08:01AM  Pluristem: Fiscal 3Q Earnings Snapshot Associated Press
07:00AM  Pluristem Reports Third Quarter Fiscal 2018 Corporate and Financial Highlights GlobeNewswire
Apr-30-18 02:46PM  FDA Clears New Drug Application For Pluristem's PLX-R18; What's Next? Benzinga +6.45%
08:41AM  Benzinga Pro's 6 Stocks To Watch Today Benzinga
07:00AM  U.S. FDA Clears Pluristems IND to Treat Victims Exposed to Acute Radiation GlobeNewswire
07:00AM  FDA clears Pluristem radiation treatment for emergency use Reuters
Apr-25-18 08:46AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga +5.00%
07:00AM  U.S. FDA Clears Pluristems Phase III Study in Treatment of Muscle Injury Following Hip Fracture Surgery GlobeNewswire
Apr-23-18 07:00AM  Pluristem and Indiana University to Initiate Joint Project Evaluating PLX-R18 in Acute Radiation Syndrome, Targeting Bridging Data for Pivotal Study GlobeNewswire
Mar-26-18 07:00AM  Roger Jeffs, Former Co-CEO of United Therapeutics, Joins Pluristem's Strategic Advisory Board GlobeNewswire
Feb-27-18 07:00AM  Pluristems PLX-R18 Improves Hematopoietic Transplantation as Reported in Scientific Journal Frontiers in Medicine GlobeNewswire +5.84%
Feb-15-18 08:47PM  What You Must Know About Pluristem Therapeutics Incs (NASDAQ:PSTI) Major Investors Simply Wall St.
Feb-07-18 07:44AM  Pluristem Issues Letter to Shareholders GlobeNewswire
Jan-31-18 02:12PM  N.Korea threats spur U.S. search for new radiation therapies Reuters
Jan-17-18 07:30AM  Wired News Pluristems PLX Cells Demonstrated Inhibition of Cancer Cell Growth in Peer-Reviewed Article ACCESSWIRE
Jan-12-18 07:00AM  Pluristems PLX Cells Significantly Inhibit Cancer Cell Growth in Newly Published Study GlobeNewswire
Jan-09-18 07:00AM  FDA Clears Pluristems Expanded Access Program to Initiate Treatments of Critical Limb Ischemia Outside of Ongoing Phase III Study GlobeNewswire
Dec-25-17 11:55AM  Does Pluristem Therapeutics Incs (NASDAQ:PSTI) Past Performance Indicate A Weaker Future? Simply Wall St.
Dec-12-17 07:30AM  Wired News VistaGen Receives US Patent on Methods for Producing Blood Cells, Platelets, and Bone Marrow Stem Cells ACCESSWIRE
05:30AM  Pluristem Granted Manufacturer Authorization and Good Manufacturing Practice (GMP) Certification by Israels Ministry of Health, Supporting Pivotal-Stage Studies GlobeNewswire
Dec-07-17 05:08AM  Pluristem to Present Data on PLX-R18 in Treatment of Acute Radiation Syndrome at American Society of Hematologys Annual Meeting GlobeNewswire
Pluristem Therapeutics Inc., together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. The company develops PLacental eXpanded (PLX) cell therapy products, including PLX-PAD cells, which is Phase III clinical trial for the treatment of critical limb ischemia (CLI) in patients unsuitable for revascularization, recovery after surgery for hip fracture, and acute radiation syndrome (ARS), as well as peripheral and cardiovascular, and orthopedic diseases. It also develops PLX-R18 cells that is in Phase I clinical trial for incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as conducts various animal studies for the evaluation of PLX-R18 for the treatment of ARS. The company has collaborative research agreement with the Berlin-Brandenburg Center for Regenerative Therapies; a license and commercialization agreement for conducting clinical trials and commercialization of its PLX-PAD product in South Korea related to the treatment CLI and intermediate claudication; and nTRACK, a collaborative project with Leitat to examine gold nano particles labeling of stem cells. It also has a collaboration agreement with the NASA's Ames Research Center to evaluate the potential of PLX cell therapies in preventing and treating medical conditions caused during space missions. Pluristem Therapeutics Inc. was founded in 2001 and is based in Haifa, Israel.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BRAUN ISAACDirectorApr 08Buy0.7050,00035,000636,208Apr 08 04:10 PM
SHORRER DORONDirectorApr 08Buy0.7014,28610,000464,744Apr 08 04:19 PM
Aberman ZamiCo-CEO & ChairmanApr 08Buy0.7071,42950,0004,939,727Apr 08 04:17 PM
YANAY YAKYCo-CEO & PresidentApr 08Buy0.7071,42950,0004,253,045Apr 08 04:15 PM
BEN-YORAM ISRAELDirectorApr 08Buy0.7071,42950,000387,235Apr 08 04:13 PM
Kwiat MoriaDirectorApr 08Buy0.7028,57120,000373,571Apr 08 04:12 PM